Guide for IPR Protection in China for the Pharmaceutical Industry

Supported by the governmental reforms and measures to encourage cost control integration and innovation as well as by China’s ambitions of bringing the health care sector to the forefront of biopharmaceutical and digital innovation, China’s pharmaceutical market offers many opportunities to European enterprises. Pharmaceutical production is a research and development (R&D) driven industry. The potential and profit of pharmaceutical companies are very dependent on the adequate protection of Intellectual Property Rights (IPR). IP is the most effective way to protect R&D and is a powerful weapon to use in the pharmaceutical market in China. This guide focuses on the principal IPR issues/provisions in the field of pharmaceuticals, namely in the areas of patent, trade mark, copyright, and technical secrets.